Given the poor survival of the MDS subgroups with biallelic TP53 inactivation, complex karyotype, and RUNX1 mutations it has to be further evaluated whether or not these MDS subtypes should be combined with AML subgroups harboring the respective genetic abnormalities for joint treatment approaches as suggested by ICC. This evidence concerns the gene RUNX1 and acute myeloid leukemia.